drugset

drugset / Trial / NCT01028911

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01028911 ↗

Phase 1 Terminated 9 enrolled Pfizer

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a study to evaluate the safety, tolerability and blood levels of PF-03654746 in subjects will mild to moderate Alzheimer's disease.

Timeline

Start: 2009-12
Primary completion: 2010-05
Completion: 2010-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-03654746	Small molecule	1 mg	Oral

Indications